Participated · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.

Participated · Series B · Mar 2026

Vitestro is a Netherlands-headquartered medical-robotics company focused on automating diagnostic blood draws with its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The CE-marked system combines multimodal imaging, advanced robotics, and artificial intelligence to locate veins, guide needle insertion, and collect blood with high precision and consistency. By standardizing venous access, the platform aims to alleviate staffing shortages, reduce variability, and improve patient experience in high-volume outpatient environments. Vitestro is currently deploying Aletta® in clinical and pre-commercial sites across Europe while pursuing a U.S. FDA De Novo clearance. Proceeds from its latest financing will fund next-generation product development, manufacturing scale-up, additional clinical studies, and the build-out of global commercial infrastructure.

Participated · Series D · Jan 2026

ViCentra develops and manufactures Kaleido, an insulin patch pump positioned as the smallest, lightest and most precise pump in its class. The system integrates with Diabeloop’s DBLG1 and DBLG2 hybrid closed-loop algorithms to deliver automated insulin therapy, and it is styled with premium materials and interchangeable aluminium shells in ten colours to resemble consumer technology rather than a traditional medical device. ViCentra currently commercialises Kaleido in parts of Europe and is expanding production capacity to meet strong demand. With fresh capital in hand, the company plans to bolster commercial execution in Germany, the Netherlands and France, while accelerating regulatory and operational preparations to enter the U.S. market. Management has set a goal to nearly triple its European user base by the end of 2026. Financially, ViCentra has secured a total of $98 million in Series D funding, including an $85 million tranche closed in September 2025 and a $13 million extension announced in the latest round.

Participated · Seed · May 2025

CryoCloud provides a cryo-electron microscopy (cryo-EM) SaaS platform that enables researchers to visualise and analyse protein structures at high resolution. The platform automates complex structural biology workflows and gives scientists access to petabytes of storage and dozens of GPUs in minutes rather than months. It uses proprietary machine-learning algorithms to process terabytes of structural data and reduce the time and cost of molecular imaging. CryoCloud aims to make cryo-EM more accessible by lowering hardware and expertise barriers and supporting structure-based drug discovery. The company plans to use the new funding to build the next generation of algorithms and expand its platform capabilities. The €2M Seed round brings total investment to €2.8M following a €500,000 Pre-Seed in 2023. Customers report higher productivity, and the customer base spans more than 25 countries across academia, biotech, and the pharmaceutical industry. CryoCloud provides a cloud-based cryoEM data analysis platform that enables fast, scalable determination of 3D protein structures for drug discovery. Co-founded in 2021 and based in Utrecht, the Netherlands, the company progressed from conceptual stages through various accelerator programs to launch its analysis platform. The platform allows scientists to determine protein structures experimentally and visualize relevant targets in their native or drug-bound state. CryoCloud has moved beyond concept to a launched product and recently closed external financing. It raised €500k in a pre-seed round led by Nina Capital with participation from Utrecht Health Seed Fund and ROM Utrecht Region. The company will use the funds to expand the capabilities of its platform.

Participated · Series A · Jul 2024

Aurea develops TreeScout, a tractor-mounted sensor system that scores individual trees for parameters such as blossom density and vigor and generates digital prescription maps for machinery. The TreeScout enables tree-level execution of farm applications throughout the season, allowing custom treatments to replace conventional full-field applications. The company reports yield increases of up to EUR 3,500 per hectare and labor and agrochemical savings of up to 90%. Aurea closed a EUR 2.8 million Series A to scale deployments of TreeScout and to fund continued development of new applications. To align with this focus, founder Bert Rijk will become Chief Product Officer and co-founder Joost Hazelhoff will take on the role of CEO. Aurea was founded in 2016 and is based in Utrecht, Netherlands.